Related Experiment Video

Updated: Jul 21, 2025

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells
11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

9.5K

Impact of supraphysiologic MDM2 expression on chromatin networks and therapeutic responses in sarcoma

Samantha M Bevill1,2,3, Salvador Casaní-Galdón1,2,3, Chadi A El Farran1,2,3

  • 1Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.

Cell Genomics
|July 26, 2023
PubMed

Insights

MDM2 overexpression impacts liposarcoma by altering gene expression and cellular behavior. High MDM2 levels in some cells confer resistance to therapies, explaining treatment failures.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • MDM2 amplification is a frequent cause of P53 inactivation in cancers.
  • Understanding MDM2's role in liposarcoma is crucial for targeted therapies.

Purpose of the Study:

  • To investigate the effects of MDM2 overexpression on chromatin, gene expression, and cellular phenotypes in liposarcoma.
  • To elucidate the mechanisms behind P53-independent functions of MDM2.
  • To explore the implications of MDM2 variability for therapeutic responses.

Main Methods:

  • Analysis of gene expression and chromatin interactions in liposarcoma.
  • Investigation of MDM2 localization and co-occupancy with transcription factors.
  • Assessment of cellular responses to MDM2 inhibitors and combination therapies.

Main Results:

  • MDM2 overexpression affects distinct regulatory circuits involving RUNX, AP-1, and P53 signaling.
  • Highly expressed MDM2 binds numerous P53-independent genes, forming complex topological interactions.
  • Overexpressed MDM2 forms nuclear foci and contributes to P53-independent phenotypes.
  • Significant cell-to-cell variability in MDM2 levels was observed.
  • MDM2-high liposarcoma cells exhibit resistance to MDM2 inhibitors and pro-apoptotic drugs.

Conclusions:

  • MDM2 overexpression drives liposarcoma progression through P53-dependent and -independent pathways.
  • Cellular heterogeneity in MDM2 expression is a key factor in therapeutic resistance.
  • Targeting MDM2 in liposarcoma requires strategies to overcome resistance in MDM2-high subpopulations.
Keywords:
MDM2P53 independentepigeneticsgenome topologyliposarcomasarcomatherapeutic resistance

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.3K
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.3K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K